Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Franklin F Pimentel"'
Autor:
Francisco José Candido dos Reis, Franklin F Pimentel, Karoline Pi Peruchi, Hélio Ha Carrara, Jessica Mc Borba, Jurandyr Moreira de Andrade, Tamara Cgf Rodrigues
Publikováno v:
Cancer Research. 81:PS13-30
Background COVID-19 pandemic presented as a challenge to breast cancer (BC) treatment, especially considering safety concerns and resource scarcity. Treatment choices have been taken mainly based on safety according to guidelines which aim hierarchic
Autor:
Franklin F Pimentel, Karoline Pi Peruchi, Daniel Guimarães Tiezzi, Jessica Mc Borba, Isabela Pc Buzatto, Jurandyr Moreira de Andrade, Tamara Cgf Rodrigues
Publikováno v:
Cancer Research. 81:PS9-27
Background The clinical benefit of adjuvant chemotherapy (CT) for breast cancer (BC) depends on several factors, like menopausal status, stage and molecular subtype. Commercial available gene signatures make possible a more accurate selection of the
Autor:
Leonardo Fleury Orlandini, Francisco Jc dos Reis, Jurandyr Moreira de Andrade, Franklin F Pimentel, Daniel Guimarães Tiezzi, Hélio Ha Carrara
Publikováno v:
Cancer Research. 80:P2-08
Background: Despite of several studies described body mass index (BMI) as a poor prognostic factor in breast cancer (BC) patients, the available data are still conflicting and the relation between obesity and BC remains unclear. In this study we eval
Autor:
Leonardo Fleury Orlandini, Francisco J.C. dos Reis, Franklin F Pimentel, Daniel Guimarães Tiezzi, Jurandyr Moreira de Andrade, Hélio Ha Carrara
Publikováno v:
Cancer Research. 80:P2-08
Background: About 20% of breast cancer (BC) subtypes are classified as HER2-positive (HER2+), recognized as a biomarker for worse prognosis. Trastuzumab (T) is a monoclonal antibody approved to treat HER2+ early BC since 2006 and included in the Worl
Autor:
J.M. de Andrade, Karoline Pi Peruchi, Hélio Ha Carrara, F. J. Candido dos Reis, Tamara Cgf Rodrigues, Franklin F Pimentel, Jessica Maria Camargo Borba
Publikováno v:
Annals of Oncology
Background: Cancer treatment during COVID-19 pandemic have been mainly focused on safety, and prioritization has been done to guide hierarchically choices according to clinical benefits considering resource scarcity Considering the magnitude of benef
Autor:
Mayara I de Paula, João Gonçalves, Daniel Guimarães Tiezzi, Franklin F Pimentel, Leandro L Alves, Juliano S Toledo, Roger Chammas, Jurandyr Moreira de Andrade
Publikováno v:
Cancer Research. 80:P5-05
Background: trastuzumab (TZB) is approved for the treatment of HER2-positive (HER2+) breast cancer in different indications and schemes. The association of pertuzumab (PTZ) in some regimens has shown to improve the clinical benefit. Recently, biosimi
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Pharmaceutical Medicine
Universidade de São Paulo (USP)
instacron:USP
Pharmaceutical Medicine
Subcutaneous (SC) trastuzumab has long been approved as a cancer treatment for early and advanced HER2-positive (HER2+) breast cancer by both the European Medicines Agency (EMA) and Agência Nacional de Vigilância Sanitária (ANVISA), the Brazilian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a44105d4b8654c5a8645a33acb3f248b
Autor:
Jurandyr Moreira de Andrade, Franklin F Pimentel, A.A.R. Da Silva, Daniel Guimarães Tiezzi, Maria Fernanda Barbirato da Mata Tiezzi
Publikováno v:
Annals of Oncology. 28:i13-i14
Publikováno v:
European Journal of Cancer. 51:S95
Autor:
J.M. de Andrade, E.R. Chagas, Daniel Guimarães Tiezzi, Marcelo Guimarães Tiezzi, Franklin F Pimentel
Publikováno v:
Annals of Oncology. 25:iv59
Aim: Despite recent advances in comprehension of cancer-immune system interactions in some tumours (i.e. melanoma and NSCLC), the role of these interactions in breast cancer has not been defined yet. In this study, we analyzed the expression of PDL-1